Shyra Gardai

Shyra Gardai is the Chief Scientific Officer at EpiBiologics. Shyra brings over 20 years of experience as an executive manager leading innovative discovery research groups focused on turning novel ideas into clinical stage therapies to battle cancer, autoimmune, and neurodegenerative diseases. During her time at Elan Pharmaceuticals and Seagen, Shyra headed the discovery and delivery of over 6 phase 1 clinical candidates that integrated novel antibody, chemistry, and protein engineering technologies. Most recently Shyra was the Vice President of Therapeutic Discovery Research at Seagen where she led a 60+ member team comprised of chemists, protein engineers, immunologist and cancer biologist focused on discovering new treatments for cancer patients. Shyra trained as an Immunologist at the University of Colorado and went on to complete a postdoctoral research fellowship in the Department of Immunology at National Jewish Health.